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Rapid labelling and covalent inhibition of
intracellular native proteins using ligand-directed
N-acyl-N-alkyl sulfonamide
Tomonori Tamura 1, Tsuyoshi Ueda1, Taiki Goto1, Taku Tsukidate1, Yonatan Shapira2, Yuki Nishikawa1,
Alma Fujisawa1 & Itaru Hamachi1,3
Selective modiﬁcation of native proteins in live cells is one of the central challenges in recent
chemical biology. As a unique bioorthogonal approach, ligand-directed chemistry recently
emerged, but the slow kinetics limits its scope. Here we successfully overcome this obstacle
using N-acyl-N-alkyl sulfonamide as a reactive group. Quantitative kinetic analyses reveal
that ligand-directed N-acyl-N-alkyl sulfonamide chemistry allows for rapid modiﬁcation of a
lysine residue proximal to the ligand binding site of a target protein, with a rate constant of
~104M−1 s−1, comparable to the fastest bioorthogonal chemistry. Despite some off-target
reactions, this method can selectively label both intracellular and membrane-bound endo-
genous proteins. Moreover, the unique reactivity of N-acyl-N-alkyl sulfonamide enables the
rational design of a lysine-targeted covalent inhibitor that shows durable suppression of the
activity of Hsp90 in cancer cells. This work provides possibilities to extend the covalent
inhibition approach that is currently being reassessed in drug discovery.
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Chemical modiﬁcation of target proteins with syntheticmolecules is a powerful methodology for the generation ofa myriad of engineered proteins, such as antibody–drug
conjugates and for the detailed study of protein function and
dynamics in living cells. Over the past two decades, bioorthogonal
methods, including chemoselective reactions with non-canonical
amino acids bearing bioorthogonal functional groups, protein/
peptide-tag-based methods, self-labelling enzyme tags and
enzyme-mediated modiﬁcations have proven to be valuable for
efﬁcient and selective protein labelling1–9. Because these reactions
are usually conducted in dilute and/or multi-molecular crowding
live cell conditions, unlike conventional chemical reactions in a
ﬂask, fast and highly chemoselective reactions are desired2,5,6.
Remarkable advances have been now achieved in both these
parameters10,11, providing researchers with useful tools for the
selective chemical modiﬁcation and engineering of protein
molecules, even under live cell conditions. Most bioorthogonal
protein modiﬁcation strategies typically require two steps: (i) the
incorporation of a bioorthogonal reaction handle, such as a
noncanonical amino acid or an enzyme domain or its substrate
peptide, into a protein of interest (POI) using genetic engineering
protocols, followed by (ii) a speciﬁc (bioorthogonal) reaction to
attach a functional molecule, such as a drug, ﬂuorophore, poly-
mer or detection tag (Fig. 1a)5. Although powerful, this two-step
method inevitably involves genetic manipulation, making it
impossible to modify endogenous (i.e. naturally occurring) pro-
teins in their native environments.
As an alternative to the bioorthogonal protein labelling
approaches, we have developed a chemical strategy based on an
afﬁnity-driven reaction involving protein–ligand interactions,
termed ligand-directed (LD) chemistry (using systems bearing
tosyl (LDT)12–14, alkyloxyacyl imidazole (LDAI)15–17 and dibro-
mophenylbenzoate (LDBB)18 reactive moieties). LD chemistry is a
simple one-step procedure employing a labelling reagent in which
a ligand for a POI and an appropriate functional molecule are
connected with a cleavable electrophilic group. The reagent
selectively binds to the POI through a speciﬁc protein–ligand
interaction, facilitating the transfer of a functional molecule to a
nucleophilic amino acid residue close to the ligand binding site via
covalent bond formation4,12. It is thus considered that the protein
selectivity and the labelling kinetics of LD chemistry may largely
rely on the recognition-driven proximity effect. However, no
quantitative kinetic analyses have been performed yet, and
therefore LD chemistry cannot be clearly evaluated, compared
with conventional bioorthogonal methods, as a complimentary
tool for protein chemical modiﬁcation.
One of the most unique characteristics of LD chemistry is that
it can target canonical amino acids of endogenous proteins with
sufﬁcient selectivity even in intact living systems without genetic
disturbance12,19. This advantage let us envision that LD chemistry
could be applied for the functional regulation of native proteins,
as well as a complement to bioorthogonal chemistry20,21. For
example, the rational design of a LD reagent that is able to
covalently attach a ligand (instead of a probe) to a protein should
be able to produce targeted covalent inhibitors (TCIs). The
development of unique TCIs may lead to potent covalent drugs,
which have undergone a recent resurgence in drug discovery
research because of their durability22,23. To date, most of the
recently developed TCIs target cysteine22–26, and expansion of
the available targetable amino acids remains a great chal-
lenge27,28. Given that our LD reagents have been shown to react
with several canonical amino acids (e.g. Lys, His, Ser, Tyr and
Glu) other than Cys12,13,15,18, our efforts to develop
a variety of LD chemistry may substantially contribute to
extending chemical warheads that can be used for TCIs (and
covalent drugs)28.
Herein, we describe a LD chemistry using N-acyl-N-alkyl sul-
fonamide derivatives (LDNASA) as the electrophilic reactive
group (Fig. 1b). Detailed kinetic analyses of in vitro protein
labelling are conducted and compared with other LD reagents,
revealing that the reaction rate of the labelling process (kL) of
LDNASA is the fastest of all the LD chemistry reagents (LDT,
LDAI and LDBB). Notably, the second-order reaction rate con-
stant (kL/Kd) of LDNASA-mediated protein labelling reaches
~104 M−1 s−1, which is comparable to enzymatic labelling and
the fastest bioorthogonal protein bioconjugations, such as inverse
electron-demand Diels-Alder (IEDDA) cycloadditions. The
excellent kinetics and bioorthogonality of LDNASA chemistry
allow for the selective and efﬁcient labelling of intracellular






































Fig. 1 Two distinct approaches for bioorthogonal protein labelling. a Schematic illustration of protein labelling through bioorthogonal chemistry. The ﬁrst
step involves the genetic incorporation of a bioorthogonal reactive handle into a protein of interest (POI) in cells. In a second step, the reactive handle
chemoselectively reacts with a designed synthetic probe. b Schematic illustration of the basic principle of ligand-directed N-acyl-N-alkyl sulfonamide
(LDNASA) chemistry. The reagent binds to a POI through a speciﬁc protein–ligand interaction, driving a chemical reaction between the reactive group and
a natural nucleophilic amino acid located on the protein surface, through the proximity effect. EWG, electron-withdrawing group; Kd, dissociation constant;
kL, ﬁrst-order rate constant for the labelling process; Nu, nucleophilic amino acid
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habitats. More interestingly, we demonstrate that the NASA
reactive group is a promising warhead for a covalent inhibitor,
which can irreversibly suppress the activity of molecular cha-
perone protein Hsp90 endogenously expressed in living cancer
cells.
Results
Design and characterisation of LDNASA reagents. While the
LD chemistries reported by our group (LDT, LDAI and LDBB)
have proved to be applicable to selective protein labelling both
in vitro and in living cells, they still suffer from sluggish reaction
rates, requiring hours to a day to achieve acceptable levels of
labelled products14,15,18,19. This motivated us to further explore
an electrophilic cleavable linker amenable to the LD strategy. We
here focused on NASA, which has been widely used as Kenner’s
safety-catch linker in solid-phase peptide synthesis29. Recently,
our group found that NASA derivatives can be used as acyl
donors for catalyst-mediated protein labelling in vitro and in
crude biological environments, such as live-cell surfaces and brain
tissues30. This study revealed that NASA is sufﬁciently stable in
neutral aqueous buffer and cell lysate conditions, and is less
susceptible to enzymatic degradation because of its unique
structure not found in nature. We thus reasoned that NASA may
have potential as a promising cleavable linker in LD chemistry for
bioorthogonal protein acylation. It has been reported that the
electrophilicity of the N-acyl group is distinctly dependent on the
electron withdrawing properties of the N-alkyl group29,31. To
identify the optimal N-alkyl group of NASA for LD chemistry,
cyano, 4-nitrophenyl, or 2,4-dinitrophenyl substituents were
selected as the electron-withdrawing groups (EWGs) on the basis
of our previous study30. We ﬁrst conducted in vitro experiments
using FKBP12 as a model target protein. We thus designed NASA
reagents 1–3 (Fig. 2a), in which a synthetic ligand for FKBP12
(SLF, reported Kd= 20 nM)32 and a biotin (Bt) afﬁnity-tag are
connected with a NASA group. The syntheses were carried out as
shown in Supplementary Methods. All of the ﬁnal compounds
were well characterised by NMR and high-resolution mass
spectroscopy.
FKBP12 labelling was conducted in test tubes by incubating
each NASA reagent (1–3) (10 µM) with puriﬁed recombinant
(wild-type) FKBP1213 (5 µM, Mw: 11 914 Da) at 37 °C in a buffer
solution (pH 7.2). The labelling reactions were monitored by
matrix-assisted desorption/ionisation time-of-ﬂight mass spectro-
metry (MALDI-TOF MS). In all cases, the molecular mass
corresponding to Bt-labelled FKBP12 (Mw: 12 140 Da) was
detected as shown in Fig. 2b and Supplementary Figure 1. Rapid
and efﬁcient FKBP12 labelling was observed in the case of 1 (98%
yield within 15 min), whereas 2 and 3 gave lower yields (22% for
2, 17% for 3) even after a 2-h incubation. The initial rate of the
reaction with 1 (84 µMmin−1) was 49- and 105-fold faster than 2
(1.7 µMmin−1) and 3 (0.8 µMmin−1), respectively (Fig. 2c). The
labelling by 1 was completely abolished in the presence of
rapamycin33 (a competitive ligand), indicating that the labelling
reaction was efﬁciently driven by an afﬁnity-mediated proximity
effect (Fig. 2b, c). This rapid and efﬁcient labelling using a NASA
containing a cyanomethyl group was also observed when
targeting Escherichia coli dihydrofolate reductase (eDHFR) using
reagent 4 containing trimethoprim (TMP) as a ligand (15 min,
80%) (Fig. 3a and Supplementary Figure 2)18,34. The results
clearly showed that the cyano group is the optimal N-alkyl group
in LDNASA reagents for efﬁcient protein labelling. The intrinsic
reactivity of the reagents was evaluated by the hydrolysis rate in
Lys44
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Fig. 2 In vitro FKBP12 labelling with LDNASA reagents 1–3. a Molecular structures of LDNASA reagents 1–3. b MALDI-TOF mass analysis of FKBP12
labelling by 1 in the absence or presence of rapamycin (Rap). Reaction conditions: 5 µM FKBP12, 10 µM 1, 100 µM Rap, 50mM HEPES buffer, pH 7.2, 37 °C.
o, native FKBP12 (Mw: 11 914); *, single-labelled FKBP12 (Mw: 12 140); **, double-labelled FKBP12 (Mw: 12 366). c Initial rates (Mmin−1) of FKBP12 labelling
by 1–3. The initial rates were estimated from the time courses of the reaction yields (inset). n.d., not detected. d The crystal structure of the FKBP12-SLF
complex (PDB:1FKG). Lys44, the major labelling site with 1, is coloured in red. The SLF ligand is shown as a green stick. Lys34 was also identiﬁed as the
second (minor) labelling site (see Supplementary Figure 5)
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aqueous buffer. The half-life of 1 was determined to be 43 h from
HPLC analysis, whereas only 5% of 2 and 3 were hydrolysed even
after incubation for 48 h at 37 °C (Supplementary Figure 3). This
suggested that the rapid labelling kinetics of N-acyl-N-cyano-
methyl sulfonamide can be mainly attributed to the higher
electrophilicity of N-acyl-N-cyanomethyl sulfonamide compared
with N-acyl-N-(mono or di) nitrobenzyl sulfonamide.
The labelling sites on FKBP12 after reaction with 1 were
identiﬁed by conventional peptide mapping analysis. FKBP12
labelled by 1 was digested with trypsin and the resultant peptide
fragments were analysed by HPLC followed by tandem mass
spectrometry. As shown in Fig. 2d, Supplementary Figures 4 and
5, Lys44 located near the ligand-binding pocket (11.3 Å from the
bound SLF ligand) was predominantly modiﬁed with biotin by 1.
We also identiﬁed the labelling site of eDHFR to be speciﬁc to
Lys32 when 4 was used (Supplementary Figure 6). These results
clearly demonstrate that NASA reagents prefer the ε-amino group
of lysine side chains, and form a chemically stable amide bond.
Kinetic analysis of ligand-directed chemistry. With the optimal
NASA reactive group in hand, we next investigated the reaction
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Fig. 3 Kinetic analysis of protein labelling with various LD reagents. a Molecular structures of LD reagents. NASA, N-acyl-N-alkyl sulfonamide; Ts, tosyl; AI,
alkyloxyacyl imidazole; BB, dibromophenyl benzoate. b MALDI-TOF MS analyses of labelling process of FKBP12 with 1. Puriﬁed FKBP12 (100 nM) was
incubated with 1 (200 nM) in HEPES buffer (50mM, pH 7.2) at 37 °C. O, native FKBP12 (Mw: 11 914); *, single-labelled FKBP12 (Mw: 12 140); **, double-
labelled FKBP12 (Mw: 12 366). c Time course of the depletion of native (non-labelled) FKBP12 during the labelling reaction with various concentrations of 1.
Puriﬁed FKBP12 (100 nM) was incubated with reagents (200–2000 nM) in HEPES buffer (50mM, pH 7.2) at 37 °C. The reaction was monitored by MALDI-
TOF MS. The pseudo-ﬁrst order reaction rates (kapp) were obtained by ﬁtting the data to Eq. (2). d The dependence of kapp upon the concentration of 1.
Kinetic parameters were obtained by ﬁtting this data to Eq. (3). e Second-order rate constants of representative bioorthogonal reactions and LD chemistries
for protein modiﬁcation. Here, the rate constants for LD chemistries indicate the range of values when the afﬁnity (Kd) of the ligand is 10−7–10−6M. The rate
constants for the bioorthogonal reactions were obtained from refs 5,10. Error bars represent s.d., n= 3
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labelling reaction of LD chemistry follows Eq. (1):
Pþ R #Kd PR!kL P ð1Þ
where P is a native (non-labelled) protein, R is the reagent, PR is
the native protein–reagent complex, P* is the labelled-protein, Kd
is the dissociation constant and kL is the rate constant for the
labelling process. When [R] > [P], the pseudo-ﬁrst-order reaction
rate (kapp) is given as follows (see Supplementary Methods)35:







1þ Kd= R½ 
ð3Þ
According to Eq. (3), a Michaelis-Menten-type saturation
curve should be obtained from the kapp-[R] plot.
The reaction time courses of FKBP12 labelling with various
concentrations of 1 (200–2000 nM) were monitored by MALDI-
TOF MS (Fig. 3b) and plotted to determine kapp using Eq. (2)
(Fig. 3c). The values of kapp obtained in this manner were then
plotted against the concentration of 1, which were well ﬁtted by
Eq. (3) (Fig. 3d). The labelling rate constant kL and the
dissociation constant Kd of 1 were determined from curve ﬁtting
analysis to be (6.1 ± 0.6) × 10−3 s−1 and (2.1 ± 0.2) × 10−7 M,
respectively (the mean of triplicate ± standard deviation (s.d))
(Table 1). The obtained Kd value was ∼1 order of magnitude
higher than the reported Kd of SLF for FKBP12 (Kd= 20 nM)32,
which indicates that the derivatization of SLF leads to slightly
drop the afﬁnity but does not appreciably reduce the binding
ability as reported by other groups32.
We then performed a kinetic characterisation of other LD
chemistries that we have previously developed, including LDT,
LDAI and LDBB (Fig. 3a). We evaluated the rate constants of 5
(LDT reagent for FKBP12), 6 (LDAI reagent for eDHFR) and 7
(LDBB reagent for eDHFR) that had been structurally optimised
for their target proteins in previous studies13,18, and compared
these kinetic parameters with the LDNASA reagents 1 and 4. In
the case of FKBP12 labelling, the kL value of LDNASA 1 was 635-
fold higher than that of LDT 5 [(9.6 ± 0.2) × 10−6 s−1], while the
obtained Kd value of 1 was almost equivalent to 5 (Table 1,
Supplementary Figure 7). In an evaluation of labelling reagents
for eDHFR, the kL value of LDNASA 4 was 2241-fold and 38-fold
higher than those of LDAI 6 [(5.8 ± 0.1) × 10−6 s−1] and LDBB 7
[(3.4 ± 0.3) × 10−4 s−1], respectively, without signiﬁcant differ-
ences in the afﬁnities of these reagents (Table 1, Supplementary
Figure 8). These quantitative kinetic parameters clearly showed
that the NASA reactive group had the largest kL of the reactive
groups developed so far.
It is conceivable that the kL/Kd value corresponds to the
second-order rate constant for the labelling reaction in LD
chemistry. Therefore, we can now directly compare the kinetics of
LD chemistries with that of other conventional bioorthogonal
reactions for protein chemical labelling (Fig. 3e). The second-
order rate constants (kL/Kd) for LDT 5, LDAI 6 and LDBB 7,
which represent the ﬁrst, second and third-generations of LD
chemistry, were estimated to be 45 ± 6M−1 s−1, 11 ± 1M−1 s−1
and 590 ± 120M−1 s−1, respectively. These values are in the same
order of magnitude as the rate constants for a widely-used copper
catalysed azide-alkyne cycloaddition (CuAAC), tetrazine-
cyclopropene cycloaddition, and photoinduced tetrazole-alkene
cycloaddition (photo-click ligation)5,6,10. On the other hand,
LDNASA reagents displayed much higher rate constants, (2.9 ±
0.4) × 104 M−1 s−1 for FKBP12 labelling with 1, and (9.3 ± 1.5) ×
103 M−1 s−1 for eDHFR labelling with 4. It is noteworthy that
these rate constants (~104 M−1 s−1) are almost comparable to the
fastest bioorthogonal protein modiﬁcations using IEDDA
cycloadditions between tetrazines and trans-cyclooctenes, and
commonly used enzymatic labelling methods, such as the SNAP/
CLIP-tag system, highlighting the rapid kinetics of LDNASA
chemistry8–10.
While the intrinsic kinetics of conventional bioorthogonal
reactions primarily relies on their reactivity, that of LD
chemistries exploiting the proximity-driven reaction via
protein–ligand recognition should strongly depend on the afﬁnity
of the reagent for the target proteins, as well as the reactivity of
the reactive group. However, it has not quantitatively been
deﬁned how much the labelling rate is affected by the ligand
afﬁnity, and how strong an afﬁnity is required to achieve efﬁcient
and selective protein labelling. To clarify the relationship between
the ligand afﬁnity and the reaction proﬁles in LD chemistry, we
subsequently sought to quantify the kinetic parameters of NASA
reagent 8 containing LLF, a low-afﬁnity ligand for FKBP12
(reported Kd= 3.5 µM)36. Prior to the kinetic analysis, we
conﬁrmed that the major labelling site of FKBP12 with 8 (Lys
44) is identical to 1 (Supplementary Figure 4). As shown in
Supplementary Figure 9, higher concentrations of 8 (µM to sub-
mM) were required for efﬁcient labelling in comparison with 1,
which is because of the low binding afﬁnity of LLF. The kinetics
assay revealed that the kL value of 8 [(7.6 ± 1.7) × 10−3 s−1] is
almost the same as that of 1 (Table 1). In stark contrast, the
second-order rate constant kL/Kd of 8 (74 ± 19M−1 s−1) was 392-
fold less than 1, because of its large Kd value [(1.0 ± 0.4) × 10−4
M]. These results clearly demonstrated that the afﬁnities of the
ligand of LD reagents predominantly determines the labelling
kinetics when the reactive group is identical, and also indicated
that a ligand with sub µM order afﬁnity is required to achieve
rapid and efﬁcient labelling with LDNASA chemistry.
Selective protein labelling in crude biological contexts. In
addition to the reaction rate and efﬁciency, target selectivity is
also important for the biological application of protein chemical
labelling. To verify the selectivity and bioorthogonality of
LDNASA chemistry, we next conducted protein labelling
Table 1 Kinetic and binding parameters of labelling reagents for FKBP12 and eDHFR
Protein Reagent kL (s−1) Kd (M) kL/Kd (M−1 s−1)
FKBP12 1 (LDNASA) (6.1 ± 0.6) × 10−3 (2.1 ± 0.2) × 10−7 (2.9 ± 0.4) × 104
5 (LDT) (9.6 ± 0.2) × 10−6 (2.1 ± 0.3) × 10−7 45 ± 6
8 (LDNASA) (7.6 ± 1.7) × 10−3 (1.0 ± 0.4) × 10−4 74 ± 19
eDHFR 4 (LDNASA) (1.3 ± 0.1) × 10−2 (1.4 ± 0.2) × 10−6 (9.3 ± 1.5) × 103
6 (LDAI) (5.8 ± 0.1) × 10−6 (5.5 ± 0.3) × 10−7 11 ± 1
7 (LDBB) (3.4 ± 0.3) × 10−4 (5.8 ± 1.1) × 10−7 (5.9 ± 1.2) × 102
The data represent the mean of triplicate ± standard deviation
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experiments in different biological environments. First, FKBP12
labelling in cell lysate was carried out using 1 and 8 to investigate
whether the afﬁnity of LD reagents affects the labelling efﬁciency
and target selectivity in crude conditions. HeLa cell lysate con-
taining 1 µM of FKBP12 was incubated with 1 (1 µM) and 8
(1–20 µM) for 1 h at 37 °C, and analysed by SDS-PAGE and
western blotting using streptavidin–horseradish peroxidase con-
jugate (SAv–HRP). As shown in lane 2 of Fig. 4a, a speciﬁc band
(12 kDa) corresponding to the biotinylated FKBP12 was clearly
observed using 1. Such selective FKBP12 labelling was inhibited
in the presence of rapamycin (lane 3), and instead, some labelling
reactions with proteins other than FKBP12 occurred owing to the
presence of 1 in the free (unbound) state. We also conducted a
titration experiment with higher concentrations of 1 (1–20 µM) to
the cell lysate (Supplementary Figure 10). Although several bands
due to unspeciﬁc labelling appeared in the ratio of reagent-to-
protein greater than one, the labelling band of FKBP12 was
predominant (the ratio of unspeciﬁc to speciﬁc labelling is less
than 0.15). When the LDNASA reagent bearing the weak afﬁnity
ligand LLF (8) was used, the FKBP12 labelling was substantially
diminished (lane 4 of Fig. 4a). To obtain the same signal intensity
as biotinylated FKBP12 labelled by 1, 20 µM of 8 was required
(lane 6 of Fig. 4a). However, such a high concentration of the
LDNASA reagent caused non-speciﬁc labelling reactions with
many non-targeted proteins. Given the afﬁnity of 1 [Kd= (2.1 ±
0.2) × 10−7 M], these results clearly indicate that the ligand afﬁ-
nity of the LDNASA reagent requires at least a sub µM order Kd
value to ensure sufﬁcient bioorthogonality (target selectivity) in
crude environments.
We then conducted intracellular endogenous FKBP12 labelling.
Mouse myoblast C2C12 cells were incubated in culture medium
containing 1 for 10–120 min at 37 °C. The cells were lysed and
analysed by western blotting. As shown in lanes 2–5 of Fig. 4b,
endogenous FKBP12 inside live cells was speciﬁcally modiﬁed
with biotin using LDNASA 1 and this labelling was abolished on
co-incubation with rapamycin (lane 6 of Fig. 4b), indicating that
recognition-driven protein labelling efﬁciently proceeded inside
the live cells. The time course of intracellular FKBP12 labelling
with LDNASA 1 is shown in Fig. 4c. Although the reaction rate
was slightly slower than that of the in vitro experiments, probably
because of the low membrane-permeability of 1, it should be
noted that the labelled band was detectable after just 10 min
incubation with 1, highlighting the rapid kinetics of LDNASA
chemistry. Quantitative western blotting analysis revealed the
labelling yield with LDNASA 1 at 60 min to be 78% of the entire
population of FKBP12 (almost quantitative at 120 min) (Fig. 4c
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Fig. 4 Target-selective protein labelling with LDNASA chemistry. aWestern blotting analysis of FKBP12 labelling in cell lysates. HeLa cell lysate was mixed
with recombinant FKBP12 (1 µM) and incubated with reagent in 50mM HEPES buffer, pH 7.2, 37 °C, 1 h. SAv-HRP, streptavidin–horseradish peroxidase
conjugate; CBB, Coomassie brilliant blue staining. The high background (smear) signals of lane 6 and 7 may suggest unspeciﬁc labelling due to a high
concentration of reagent (20 µM), whereas such background signals were less in lanes 1–5 (1–5 µM of reagent). bWestern blotting analysis of endogenous
FKBP12 labelling in live C2C12 cells. The cells were treated with 1 or 5 (1 µM) for 0–120min at 37 °C in medium. c Time course plot of the endogenous
FKBP12 labelling with 1. d Molecular structures of LDNASA 9 and LDAI 10 for FR labelling. e In-gel ﬂuorescence and western blotting analysis of
endogenous FR labelling in KB cells. The cells were treated with 9 or 10 (1 µM) for 0–60min at 37 °C in medium. FA, Folic acid (competitive inhibitor). f
Time proﬁle of the endogenous FR labelling with 9. I and I30min are band intensities of Oregon Green-labelled FR at the indicated time point and at 30min,
respectively. Error bars represent s.d., n= 3
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and Supplementary Figure 11), while the LDT reagent 5, which
has successfully achieved intracellular FKBP12 labelling in our
previous work13, failed to label FKBP12 in C2C12 cells in that
time frame (<120 min) (lane 7 of Fig. 4b).
The applicability of LDNASA chemistry to membrane proteins
was demonstrated by folate receptor (FR) labelling in KB cells
with LDNASA 9 containing the methotrexate (MTX) ligand
(Kd ≈ 200 nM for FR)37 and an Oregon-Green probe (Fig. 4d).
The speciﬁc ﬂuorescent band of the labelled-FR was observed in
in-gel ﬂuorescence detection (Fig. 4e), and the labelling reaction
was completed within 30 min using LDNASA 9 (Fig. 4f), while
negligible signal was observed with the previous LDAI reagent 10
in such a short time. Overall, these results demonstrated that
LDNASA reagents can rapidly label both endogenous intracel-
lular and membrane-associated proteins in a highly speciﬁc
manner in native multi-molecular crowding biological contexts.
Design of a NASA-based irreversible inhibitor for Hsp90. LD
reagents are normally designed to incorporate a synthetic probe
into a protein, but conversely, they can also be used to attach the
ligand moiety (instead of the probe) to a protein by switching the
linkage direction. We expected that such a LD reagent may act as
an irreversible inhibitor of the target protein22,23. As demon-
strated above, LDNASA chemistry allows rapid and efﬁcient
covalent modiﬁcation of canonical nucleophilic amino acids (e.g.
the ε-amino group of non-catalytic lysine) of the target (endo-
genous) protein. Given these unique properties, which cannot be
addressed by other bioorthogonal methods, we envisioned that
NASA-based protein labelling could serve as a useful strategy to
develop a selective covalent inhibitor, in which the NASA group
is used as a warhead for the covalent bond formation between a
ligand and the target protein. As a proof-of-principle, we chose
Hsp90 as a target protein38,39. Recent studies have revealed that
the chaperone activity of Hsp90 is closely associated with the
pathology of various diseases, including tumourigenesis, inﬂam-
mation and neurodegenerative diseases. Therefore, Hsp90 is now
considered an attractive drug target, and covalent inhibition of its
chaperone activity holds promise as a therapeutic strategy for
treatment of these conditions40.
Prior to the development of a covalent inhibitor for Hsp90, we
investigated whether the NASA-based reagents can selectively
react with endogenous Hsp90 in live cells. We designed the
LDNASA reagent 11, which consists of PU-H7141,42, a speciﬁc
(reversible) ligand for the N-terminal ATP binding domain of
Hsp90, and ﬂuorescein diacetate (AcFL) as the detection probe
(Fig. 5a). It was revealed that LDNASA 11 labelled endogenous
Hsp90 (both α and β isoforms) in breast cancer SKBR3 cells after
3 h with sufﬁcient selectivity even using high concentrations of
the reagent (~10 µM) (Fig. 5b, Supplementary Figures 12 and 13).
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11 (L) vs DMSO (H) 11 (L) vs 11 + PU-H71 (M)
Fig. 5 Selective and site-speciﬁc labelling of endogenous Hsp90 in live cells. a Molecular structure of LDNASA 11 for Hsp90 labelling. b SDS-PAGE and
western blotting analysis of the labelling reaction in live SKBR3 cells. The cells were treated with 11 (0.5 µM) in the absence or presence of PU-H71 (10 µM)
for 3 h at 37 °C in medium (pH 7.4). After washing, the cells were lysed and analysed by in-gel ﬂuorescence and western blotting using anti-Hsp90
antibody. c Workﬂow for TMT-based quantitative LC-MSMS analysis of proteins labelled with 11. After in-gel digestion, obtained peptide fragments were
modiﬁed with Light- (L-), Medium- (M-), or Heavy- (H-) TMT reagent for samples treated with 11 (0.5 µM, 3 h), 11 with PU-H71 (10 µM), or DMSO,
respectively. d L/H ratio plots for total proteins identiﬁed in experiments comparing cells treated with 11 versus DMSO. Proteins with median L/H ratios >5
are assigned as 11-labelled proteins (red plots). e L/M ratios (11 versus 11 with PU-H71) of proteins assigned as 11-targets. Gene names of ligand-speciﬁc
targets (L/M ratios >1) and off-targets (L/M ratios <1) are written in red and black, respectively. f The crystal structure of the N-terminal ATP binding
domain of Hsp90α–PU-H71 complex (PDB ID: 2FWZ). The residue (Lys 58) modiﬁed with 11 and 12 is highlighted in red, and the PU-H71 ligand is coloured
in blue
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competitively bind the ATP-binding site, indicating the labelling
occurred by an afﬁnity-driven proximity effect (Supplementary
Figure 14).
While these gel based analyses showed the selective labelling of
Hsp90, we more carefully evaluated off-target proteins of 11 in
live cells by a quantitative mass spectrometry using tandem mass
tag (TMT) labelling (Fig. 5c)43. The labelled proteins were
enriched by immunoprecipitation with an anti-ﬂuorescein anti-
body and tryptically digested in gel. Digested peptides were
modiﬁed with Light- (L-), Medium- (M-), or Heavy- (H-) TMT
reagent for samples treated with 11, 11 with PU-H71 (as
competitive condition), or DMSO (vehicle), respectively, and
mixed in a 1:1:1 ratio for LC-MSMS analysis. We performed three
experimental replicates, in which proteins detected and quantiﬁed
at least twice were selected as identiﬁed proteins. According to the
related approach of Cravatt et al44, the proteins having L/H (11/
DMSO) ratios >5 were deﬁned as 11-labelled proteins. We also
designated the ligand-speciﬁc targets or off-targets as proteins
exhibiting L/M (11/11 with PU-H71) ratios more or less than 1,
respectively. On the basis of these criteria, we identiﬁed 6 proteins
that react with 11, including three ligand-speciﬁc targets (Hsp90α
(HSP90AA1), Hsp90β (HSP90AB1), and Grp94 (HSP90B1)) and
three off-targets (Trifunctional enzyme subunit α (HADHA),
Tubulin-α (TUBA1B), and ADP/ATP translocase 3 (SLC25A6))
(Fig. 5d, e and Supplementary Data 1). Notably, the targeted
Hsp90α and Hsp90β showed the highest L/H ratios among
identiﬁed proteins (13.5 and 9.3, respectively). Grp94, a HSP90
isomer, was previously reported to be a PU-H71 speciﬁc target.
TRAP-1, another Hsp90 isomer that can bind PU-H71, on the
other hand, was not identiﬁed as 11-target by our criteria45. Both
the gel-based analysis and chemoproteomic data clearly demon-
strated the high selectivity of the NASA reagent for Hsp90,
although there are a few off-target proteins.
The labelling site of cellular Hsp90α was identiﬁed to be Lys58
located at the entrance of the ligand-binding pocket of the ATP
binding domain of Hsp90α (Fig. 5f and Supplementary Figure 15).
On the basis of the crystal structure (PDB ID: 2FWZ), the labelled
lysine residue of Hsp90α, which is conserved in Hsp90β, is close
to the isopropyl amine moiety of the PU-H71 ligand at a distance
of approximately 6.2 Å (Fig. 5f and Supplementary Figure 16).
Given all of these data, we rationally designed the NASA-based
covalent inhibitor 12, in which a PU-H71 ligand is connected to a
NASA warhead with a 6.3 Å–linker (Fig. 6a, b). The quantitative
and single covalent attachment of the PU-H71 ligand was
conﬁrmed to be Lys 58, identical to the labelling site with
LDNASA 11, using a recombinant N-terminal ATP binding
domain of Hsp90 and 12 in test tube experiments (Fig. 5f,
Supplementary Figures 17 and 18). The kinetic study gave us the
afﬁnity (Ki) of 12 for Hsp90 to be 62 nM, which is in good
agreement with the reported IC50 value (~50 nM) of PU-H71
ligand (Supplementary Figure 19)41. Also, the second-order rate
constant of the covalent inhibition was estimated to be 2.9 × 104
M−1 s−1 equivalent to that of LDNASA 1 (Table 1). The covalent
bond formation of 12 with intracellular Hsp90 in live cells was
next evaluated by an inhibition experiment in which the
ﬂuorescein labelling ratio of Hsp90 with 11 in the presence of
12 or PU-H71 was compared. SKBR3 cells were pre-treated with
PU-H71 or 12 (1–10 µM) for 3 h, followed by extensive washing
with culture medium to remove unbound inhibitors, and then
labelled with 11 (0.5 µM). As shown in Fig. 6c, pre-treatment with
compound 12 strongly inhibited the ﬂuorescent labelling. In
contrast, non-covalent PU-H71 failed to block the labelling
reaction under such washing conditions. These results clearly
indicate the durable occupancy of compound 12 in the binding
site of intracellular Hsp90 because of the covalent bond, whereas
the noncovalent (reversible) inhibitor PU-H71 was readily
washed out resulting in a loss of potency. These results
encouraged us to examine the potential proliferation-inhibiting
effects of compound 12 on tumour cells. SKBR3 cells were treated
with PU-H71 or 12 for 3 h, followed by washing with medium.
The cells were further incubated in medium for 69 h, and the cell
viability was evaluated with the WST-8 assay46. While the long-
term incubation of the cells with PU-H71 (for 72 h) showed
remarkable cytotoxicity, treatment with PU-H71 for only 3 h
almost abolished the cytotoxicity due to the rapid washout from
cells (Fig. 6d and Supplementary Figure 20). On the other hand,
3 h incubation of compound 12 clearly showed a growth
inhibitory effect at a concentration of 1–10 µM (Fig. 6d). We
also examined the expression levels of client proteins of Hsp90
(Fig. 6e, f). As previously reported41, when PU-H71 (1 μM) was
treated for 24 h (without washing), the western blotting bands of
major Hsp90-client proteins, such as HER2, cRaf, Akt and pAkt,
dramatically decreased relative to the vehicle control, which was
reasonably ascribed to the inhibition of the chaperone activity of
Hsp90 by PU-H71 (Supplementary Figure 21). Such a decrease in
Hsp90-client proteins was also observed in the cells that were
treated with 12 for 3 h followed by washing and further
incubating for 21 h (lanes 3–5 of Fig. 6e), whereas PU-H71 did
not signiﬁcantly affect the band intensities of client proteins
under the same washing conditions (lanes 1 and 2). These results
explicitly demonstrated that the NASA-based covalent inhibitor
12 is a potent long-term (irreversible) inhibitor of the chaperone
activity of intracellular Hsp90, which is in agreement with the
observed cytotoxicity effect of 12.
Discussion
In summary, we have developed LDNASA chemistry that shows
rapid reaction kinetics with sufﬁcient target selectivity and
bioorthogonality under native live cell conditions. The second-
order rate constant was comparable to that of the fastest bioor-
thogonal protein modiﬁcation methods. We also found that the
NASA reactive group is capable of labelling the ε-amino group of
non-catalytic Lys residues. It is generally considered that ~99.9%
of the Lys residues on protein surface are protonated, which
suppresses their nucleophilicities (reactivities) under physiologi-
cal pH27. However, our data strongly suggest that the chemical
labelling of the Lys residues can proceed by the close proximity of
the NASA reactive group to the ε-amino group of Lys. While the
ligand-directed chemistry requires an appropriate ligand and may
suffer to some extent from the unspeciﬁc labelling in biological
crude environments, the present study indicated that this lim-
itation can be addressed by careful design of reagents (use of a
ligand with a Kd value of sub µM order) and thorough optimi-
sation of reaction conditions. Moreover, we demonstrated that
the mass spectroscopy-based analysis is quite powerful for the
proteome-wide characterisation of the possible off-target proteins
in this method. These results provide deep insights and important
guidelines for practical use of not only LDNASA chemistry but
also other proximity-driven protein labelling in living systems.
We also demonstrated that NASA-based protein modiﬁcation
is applicable for the irreversible suppression of native protein
functions in living cells. To the best of our knowledge, this study
is the ﬁrst report of covalent inhibition of the N-terminal ATP
binding domain essential for the catalytic chaperone activity of
Hsp90. Inhibition of the ATPase activity in an irreversible fashion
should be particularly effective in enhancing the drug potency
inside cells, where a high concentration of endogenous ATP/ADP
(1–10 mM) may competitively attenuate the potency of reversible
inhibitors47. Furthermore, the present study clearly showed that
the NASA warhead is able to react with a lysine residue that is
close to the ligand binding site, but not the catalytic residue.
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There have been few surface lysine-targetable inhibitors devel-
oped to date27,48–50, and in general, it is quite difﬁcult to
rationally design such an inhibitor, mainly because of the lack of
suitable warheads for such less-reactive residues51. In this respect,
the NASA reactive group should have great potential as a versatile
electrophile for lysine-targeted irreversible inhibition and is
expected to expand the scope of targetable proteins in covalent
drug development.
Methods
Synthesis. All synthetic procedures and compound characterisations are described
in Supplementary Methods.
General materials for biological experiments. All biological reagents were pur-
chased from Sigma-Aldrich, Tokyo Chemical Industry (TCI), Wako Pure Chemical
Industries, Sasaki Chemical, Bio-Rad, Thermo Fisher Scientiﬁc, Nacalai Tesque or
Watanabe Chemical Industries, and used without further puriﬁcation, unless
otherwise noted. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and western blotting were carried out with a Bio-Rad Mini-Protean III
electrophoresis apparatus. Fluorescence gel images and chemical luminescent sig-
nals using Chemi-Lumi one (Nacalai Tesque) or ECL Prime (GE Healthcare) were
obtained by an imagequant LAS4000 (Fujiﬁlm). Matrix-assisted laser desorption/
ionisation time-of-ﬂight mass spectrometry (MALDI-TOF MS) spectra were
measured with an Autoﬂex III, Ultraﬂex III or UltraﬂeXtreme (Bruker Daltonics)
using α-cyano-4-hydroxycinnamic acid (CHCA) or sinapic acid as the matrix. UV-
vis absorption spectra were obtained with a Shimadzu UV-2550 spectro-
photometer. Reversed-phase HPLC (RP-HPLC) was carried out on a Hitachi
Chromaster system equipped with a 5430 UV-vis detector, a 5440 ﬂuorescence
detector, and a YMC-Pack ODS-A column (5 μm, 250 × 4.6 mm) at a ﬂow rate of
1.0 mL/min. All runs used linear gradients of acetonitrile containing 0.1% tri-
ﬂuoroacetic acid (TFA) and 0.1% aqueous TFA.
FKBP12 labelling in vitro. Recombinant human FKBP12 was obtained as
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Fig. 6 Irreversible inhibition of intracellular Hsp90. a Schematic illustration of reaction mechanism of NASA-based covalent inhibitor. b Molecular
structures of PU-H71 (non-covalent inhibitor) and NASA-based covalent inhibitor 12. c In-gel ﬂuorescence analysis of ﬂuorescein labelling of Hsp90 with 11
in SKBR3 cells after inhibitor washout. After cells were incubated with various concentrations of PU-H71 or 12 for 3 h, the cells were washed with medium
and further incubated with 11 for 3 h. The cells were washed, lysed and analysed by in-gel ﬂuorescence imaging. Error bars represent s.d., n= 3. d Viability
of the cells 69 h after PU-H71 or 12 washout. Data represent mean values ± standard error of the mean (s.e.m.) for three (PU-H71) or six (compound 12)
independent experiments. e Western blotting analysis of the destabilization of client proteins induced by inhibiting Hsp90 chaperone activity, and f the
normalised band intensities. Cells were treated with PU-H71 or 12 for 3 h, followed by washing with media and further incubation for 21 h. The protein band
intensity was normalised to DMSO control (lane 1). β-actin is a control as a non-Hsp90 client protein. Error bars represent s.d., n= 3
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reagent (10 μM) in the absence or presence of rapamycin (20 μM) in HEPES buffer
(50 mM, pH 7.2) at 37 °C. Aliquots at different time points were taken and then
desalted using a Ziptip-C4 (Merck), and the labelling yields were determined by
MALDI-TOF MS (matrix: CHCA).
Peptide mapping of the Bt-labelled FKBP12. Puriﬁed FKBP12 (39.4 μM) was
incubated with LDNASA 1 or 8 (39.4 μM) in HEPES buffer (50 mM, pH 7.2) at 37 °
C. After 0.5 h, the labelled FKBP12 was puriﬁed by size-exclusion chromatography
using a TOYOPEARL HW-40F column with pH 8.0 50 mM HEPES buffer. To this
solution, urea (at a ﬁnal concentration of 2M) and Trypsin (Trypsin/substrate
ratio= 1/5 (w/w)) were added. After incubation at 37 °C for 24 h, the digested
peptides were separated by analytical RP-HPLC. The collected fractions were
analysed by MALDI-TOF MS (matrix: CHCA) and the labelled fragment was
further characterised by MALDI-TOF-TOF MS/MS analysis. To determine the
minor labelling site, the digested peptides were desalted using a Ziptip-C18
(Merck) and analysed by nanoﬂow reverse liquid chromatography followed by
tandem MS, using a LTQ Orbitrap XL hybrid mass spectrometer (Thermo Fisher
Scientiﬁc). For LTQ-Orbitrap XL, a capillary reverse phase HPLC-MS/MS system
composed of an Agilent 1100 series gradient pump equipped with Calco C2 valves
with 150-µm ports, and LTQ-Orbitrap XL hybrid mass spectrometer equipped with
an XYZ nanoelectrospray ionisation (NSI) source (AMR). Samples were auto-
matically injected using PAL system (CTC analytics, Zwingen, Switzerland) into a
peptide L-trap column OSD (5 µm, AMR) attached to an injector valve for desa-
linating and concentrating peptides. After washing the trap with MS-grade water
containing 0.1% triﬂuoroacetic acid and 2% acetonitrile (solvent C), the peptides
were loaded into a nano HPLC capillary column (C18 packed with the gel particle
size of 3 µm, 0.1 × 150 mm, Nikkyo Technos, Tokyo Japan) by switching the valve.
Water containing 0.1% formic acid (solvent A) and 80% acetonitrile containing
0.1% formic acid (solvent B) were used as eluents. The column was developed with
the concentration gradient of acetonitrile as follows: from 5% B to 35% B in 150
min, from 45% B to 95% B in 1 min, sustaining 95% B for 20 min, from 95% B to
5% B in 1 min, and ﬁnally re-equilibrating with 5% B for 8 min. The Xcalibur
2.1 system (Thermo Fisher Scientiﬁc) was used to record peptide spectra over the
mass range of m/z 350–1500, and MS/MS spectra in information-dependent data
acquisition over the mass range of m/z 150–2000. Repeatedly, MS spectra were
recorded followed by two data-dependent collision induced dissociation (CID) MS/
MS spectra generated from two highest intensity precursor ions. Multiple charged
peptides were chosen for MS/MS experiments due to their good fragmentation
characteristics. MS/MS spectra were interpreted, and peak lists were generated by
Proteome Discoverer 1.4.1.14 (Thermo Fisher Scientiﬁc). Searches were performed
using the SEQUEST HT (Thermo Fisher Scientiﬁc) against the latest uniprot
database for whole Human proteome (Homo sapiens, 9606). The database was
searched for tryptic-digested peptides with up to three miscleavages. Dynamic
modiﬁcations of biotin on any amino acids and oxidation on methionine were
searched with peptide mass tolerance at 10 ppm and MS/MS mass tolerance of
0.6 Da. The resultant data set was ﬁltered to a maximum false discovery rate
(FDR) of 0.01.
eDHFR labelling in vitro. Recombinant eDHFR was obtained as described
in Supplementary Methods. Puriﬁed eDHFR (10 μM) was incubated with 4 (20
μM) in the absence or presence of trimethoprim (TMP) (50 µM) in HEPES buffer
(50 mM, pH 7.2) at 37 °C. Aliquots at different time points were taken and then
desalted using a Ziptip-C4, and the labelling yields were determined by MALDI-
TOF MS (matrix: sinapic acid)
Peptide mapping of the Dc-labelled eDHFR. Recombinant eDHFR (50 μM) was
incubated with LDNASA 4 (50 μM) in HEPES buffer (50 mM, pH 7.2) at 37 °C for
1 h. The Dc-labelled eDHFR was puriﬁed by size-exclusion chromatography
(TOYOPEARL HW-40F column, TOSOH) with pH 8.0 50 mM HEPES buffer. The
protein was denatured with urea (at a ﬁnal concentration of 4M), and then treated
with Trypsin (Trypsin/substrate ratio= 1/10 (w/w)) at 37 °C for 58 h. The digested
peptides were separated by RP-HPLC with UV (absorbance at 220 nm) and
ﬂuorescent detector (λex= 430 nm, λem= 480 nm), followed by the analysis of the
collected fractions by MALDI-TOF MS and MS/MS analysis.
Evaluation of stabilities of LDNASA reagents. LDNASA 1–3 (10 μM) and
internal standard (Trimethoprim, 10 μM) were incubated in HEPES buffer (50
mM, pH 7.2) at 37 °C. Samples at different time points were taken and analysed by
RP-HPLC.
Kinetic analysis of FKBP12 labelling. Puriﬁed FKBP12 (100 nM) was incubated
with reagent (200–2000 nM) in HEPES buffer (50 mM, pH 7.2) at 37 °C. Aliquots
at different time points were taken, and the reaction was immediately quenched
using a Ziptip-C4. The residual ratio of nonlabelled protein ([P]+ [PR]/[P]0) were
determined by MALDI-TOF MS (matrix: CHCA). The pseudo-ﬁrst order reaction
rates (kapp) were obtained by ﬁtting the data to Eq. (2). Kinetic parameters were
obtained by ﬁtting the data to Eq. (3).
Kinetic analysis of eDHFR labelling. Puriﬁed eDHFR (300 nM) was incubated
with reagent (0.6–6 µM) in HEPES buffer (1 mM, pH 7.2) at 37 °C. Aliquots at
different time points were taken, and the reaction was immediately quenched by
mixing acidic matrix solution (10 mg/mL sinapic acid, 0.1% TFA, 50% acetonitrile
in water). The residual ratio of nonlabelled protein ([P]+ [PR]/[P]0) were deter-
mined by MALDI-TOF MS, and the kinetic parameters were obtained by the
method described above.
FKBP12 labelling in HeLa cell lysate. HeLa cells (kindly gifted from Prof. Yoshiki
Katayama) (1×107 cells) were suspended in HEPES buffer (50 mM, pH 7.2) con-
taining 1% protease inhibitor cocktail set III (Calbiochem) and lysed by Potter-
Elvehjem homogeniser at 4 °C. The lysate was centrifuged at 16 000 × g for 3 min,
and the supernatant was collected. Protein concentration was determined by BCA
assay and adjusted to 0.5 mg/mL. This solution was incubated with recombinant
FKBP12 (ﬁnal concentration 1 µM) and 1 (1 µM) or 8 (1–20 µM) in the absence or
presence of Rapamycin (10 or 20 µM) for 1 h at 37 °C. The reaction mixture was
mixed with 1/4 volume of 5 × sample buffer (pH 6.8, 312.5 mM Tris–HCl, 25%
sucrose, 10% SDS, 0.025% bromophenol blue) containing 250 mM DTT and
incubated for 1 h at 25 °C. The samples were analysed by western blotting using
Streptavidin-HRP conjugate (SAv-HRP, Thermo, S911, 1:5000) and Coomassie
Brilliant Blue (CBB) stain.
Chemical labelling of endogenous FKBP12 in C2C12 cells. Mouse myoblast
C2C12 cells (ATCC) (2.0 × 105 cells) were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% foetal bovine serum (FBS, Gibco),
penicillin (100 units/ml), streptomycin (100 mg/ml), and amphotericin B (250 ng/
ml), and incubated in a 5% CO2 humidiﬁed chamber at 37 °C. The cells were then
incubated in FBS-free DMEM containing reagent (1 μM) at 37 °C for 120 min. As
control experiments, the labelling was conducted in the presence of Rapamycin (10
μM). For western blot analysis, after washing twice with PBS, the cells were lysed
with RIPA buffer (pH 7.4, 25 mM Tris–HCl, 150 mM NaCl, 0.1% SDS, 1% Nonidet
P-40, 0.25% deoxycholic acid) containing 1% protease inhibitor cocktail set III
(Calbiochem). The lysed samples were collected and centrifuged (15 200 × g, 10
min at 4 °C). The supernatants were mixed with 1/4 volume of 5× sample buffer
(pH 6.8, 312.5 mM Tris–HCl, 25% sucrose, 10% SDS, 0.025% bromophenol blue)
containing 250 mM DTT and incubated for 1 h at 25 °C. The samples were sub-
jected to SDS-PAGE and electro-transferred onto an Immun-Blot PVDF mem-
brane (Bio-Rad). The labelled FKBP12 was detected by chemiluminescence analysis
using Streptavidin-HRP conjugate, rabbit anti-FKBP12 antibody (Abcam, ab2918,
1:1000) and anti-rabbit IgG-HRP conjugate (CST, #7074 S, 1:5000).
Chemical labelling of endogenous FR in KB cells. KB cells were obtained from
Cell resource centre for biomedical research (Institute of development, aging and
cancer, Tohoku university), tested negative for mycoplasma contamination, and
used without further authentication, to demonstrate endogenous FR labelling in
live cell contexts because FR is highly expressed in the cells. KB cells (2.0 × 105
cells) were cultured in folate-free RPMI1640 (Gibco) supplemented with 10% FBS,
penicillin (100 units/ml), streptomycin (100 mg/ml), and amphotericin B (250 ng/
ml), and incubated in a 5% CO2 humidiﬁed chamber at 37 °C. The cells were
washed three times with folate- and FBS-deﬁcient RPMI1640, and then incubated
in the medium containing reagent (1 μM) at 37 °C. The labelling was also con-
ducted in the presence of folate (25 μM) as a negative control. After washing three
times with PBS, the cells were lysed on ice by RIPA buffer containing 1% protease
inhibitor cocktail set III. The lysate was collected into a tube and centrifuged for 10
min at 15 200 × g. The supernatant was mixed with the same volume of 5 × sample
buffer and incubated for 1 h at 25 °C. After SDS-PAGE, ﬂuorescence signals in the
gel were detected by LAS4000. The expression of FR was conﬁrmed by western
blotting analysis using anti-FR antibody (Abcam, ab125030, 1:1000) and anti-
rabbit IgG-HRP conjugate.
Chemical labelling of endogenous Hsp90 in SKBR3 cells. SKBR3 human breast
cancer cells (ATCC) (4.0 × 105 cells) were cultured in McCoy’s 5 A supplemented
with 10% FBS, penicillin (100 units/ml), streptomycin (100 mg/ml), and ampho-
tericin B (250 ng/ml), and incubated in a 5% CO2 humidiﬁed chamber at 37 °C.
The cells were then incubated in HEPES-modiﬁed McCoy’s 5 A (FBS-free) con-
taining reagent (indicated concentration) at 37 °C for indicated time. As control
experiments, the labelling was conducted in the presence of competitive inhibitors.
After labelling, the cells were washed twice with PBS, and lysed with RIPA buffer.
The lysed sample was collected and centrifuged (15 200 × g, 10 min at 4 °C). The
supernatant was mixed with 1/4 volume of 5 × sample buffer and vortexed for 1 h
at room temperature. The samples were subjected to in-gel ﬂuorescence and
western blotting analysis using anti-Hsp90 antibody HRP conjugate (CST, #79641,
1:1000).
Identiﬁcation of 11-labelled proteins in live cells. SKBR3 human breast cancer
cells (2.0 × 106 cells) were seeded on a 10 cm dish and cultured for 3 days in
McCoy’s 5A in a 5% CO2 humidiﬁed chamber at 37 °C. The cells were then
incubated in HEPES-modiﬁed McCoy’s 5A (FBS-free) containing 11 (0.5 µM) or
DMSO (vehicle) at 37 °C for 3 h. As competitive experiments, the labelling was
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conducted in the presence of PU-H71 (10 µM). After labelling, the cells were
washed twice with PBS, and lysed with RIPA buffer. The lysed sample was collected
and centrifuged (15 200 × g, 10 min at 4 °C). The supernatant was mixed with
chilled acetone and incubated overnight at −80 °C. The protein precipitates were
solubilized by sonication in 1 mL of RIPA buffer containing 1% SDS, and then 10-
fold diluted with RIPA buffer to reduce SDS concentration to c.a. 0.1%. The protein
solution (containing 1 mg of protein) was mixed with Protein G Sepharose 4 Fast
Flow (GE Healthcare) and rotated at 4 °C for 1 h. After removal of the beads, the
remaining supernatant was mixed with anti-ﬂuorescein antibody (Abcam, ab19491,
7:10000) and rotated at 4 °C for 1 h, followed by addition of fresh Protein G
Sepharose 4 Fast Flow and further incubation at 4 °C for 4 h. The beads were
washed ﬁve times with RIPA buffer and once with PBS. Proteins were eluted from
the beads by addition of 2 × sample buffer containing 100 mM DTT and boiling at
95 °C for 5 min. The samples were subjected to a 7.5% SDS–PAGE gel (Mini-
PROTEAN TGX Gels, BioRad), and electrophoresed as the migration distance of
dye front is about 10 mm. Each lane was excised (height, 10 mm), and treated with
a 47.5% methanol / 47.5% pure water / 5% acetic acid for 20 min, a 50% methanol /
50% pure water for 10 min, and in pure water for 10 min. The gel pieces were
dehydrated with 100% acetonitrile, and then swelled with 200 μL of 100 mM TEAB
(triethylamine bicarbonate) buffer containing 10 mM DTT and heated at 56 °C for
30 min. The solutions were replaced with 200 µL of 100 mM TEAB buffer con-
taining 55 mM iodoacetamide and incubated for 45 min in the dark. The gel pieces
were washed with 100 mM TEAB buffer and dehydrated in acetonitrile. This step
was repeated once. The gels were reswelled in 100 mM TEAB buffer containing 10
ng/μL Sequencing Grade Trypsin (Promega) and incubated overnight at 37 °C. To
the gels, 50 μL of an extraction solution (50% acetonitrile, 0.1% TFA) was added.
After 10 min incubation, the supernatants were collected to new tubes, and this
process was repeated twice. Extracted peptides were dried in vacuo and reconstituted
with 25 μL of 100mM TEAB buffer. 6-plex TMT reagents (Thermo Fisher Scientiﬁc)
were used for quantitative MS analysis of samples treated with 11, 11 with PU-H71,
or DMSO (light tag for 11, medium tag for 11 with PU-H71, and heavy tag for
DMSO) according to manufacturer’s instruction. Brieﬂy, the digested peptides were
allowed to react with TMT reagents for 1 h at room temperature, and the reactions
were quenched by addition of 5% hydroxylamine. Three samples were mixed in a
1:1:1 ratio and dried. The peptides were dissolved in 200 μL of 5% acetonitrile / 0.1%
TFA mixture and puriﬁed by a GL-Tip SDB (GL Sciences) according to the manu-
facturer’s instruction. Brieﬂy, the tip was washed with 5% acetonitrile / 0.1% TFA
mixture, and peptides were eluted by 80% acetonitrile / 0.1% TFA. After removing the
solvent, the residue was dissolved in 43 µL of a 5% acetonitrile / 0.1% TFA mixture.
NanoLC–MS/MS analyses were carried out on a Q-Exactive mass spectrometer
(Thermo Fisher Scientiﬁc) equipped with an Ultimate 3000 nanoLC pump (AMR).
Samples were automatically injected using PAL system into a peptide L-trap column
OSD (5 µm) attached to an injector valve for desalinating and concentrating peptides.
After washing the trap with MS-grade water containing 0.1% TFA and 2% acetoni-
trile, the peptides were loaded into a nano HPLC capillary column (C18 packed with
the gel particle size of 3 µm, 0.1 × 150mm, Nikkyo Technos, Tokyo Japan). The
injection volume was 5 μL and the ﬂow rate was 500 nL/min. The mobile phases
consisted of (A) 0.1% acetic acid and (B) 0.1% acetic acid and 80% acetonitrile. A two-
step linear gradient of 5–45% B in 60min, 45–95% B in 1min, 95% B for 20min was
performed. Spray voltage, the mass scan ranges, and the normalised collision energy
were set to be 2000V, m/z 120–1800, and 30, respectively. Top ﬁve precursor ions
were selected in each MS scan for subsequent MS/MS scans. A lock mass function was
used to obtain constant mass accuracy during gradient. The MS data was analysed by
Proteome Discoverer 2.2 (Thermo Fisher Scientiﬁc). Searches were performed using
Sequest HT (Thermo Fisher Scientiﬁc) against UniprotKB/Swiss-Prot release 2017-
07-05 with a precursor mass tolerance of 10 ppm, a fragment ion mass tolerance of
0.02 Da. Trypsin speciﬁcity allowed for up to two miscleavages. TMT labelling on
lysine residues and peptide N-termini, and cysteine carbamidomethylation were set as
static modiﬁcations. Methionine oxidation was set as a dynamic modiﬁcation. A
reversed decoy database search was carried out to set FDRs of less than 0.01 both at
peptide and protein levels. Proteins detected with a minimum of three peptides at
least twice were selected as identiﬁed proteins in three replicates, in which keratin
proteins were removed. Protein quantiﬁcation was performed by averaging relative
peak intensities of the TMT reporter signals across all quantiﬁed peptides.
Identiﬁcation of labelling site of Hsp90 labelled with 11. Before labelling, HeLa
cells (1.2 × 106 cells) were seeded on 10 cm dish and incubated in DMEM sup-
plemented with 10% FBS for 48 h at 37 °C under 5% CO2. After washing twice with
PBS, the cells were incubated in DMEM (HEPES-modiﬁed, FBS free) containing
LDNASA 11 (0.5 µM) for 3 h. The cells were washed with PBS, and lysed by three
successive freeze and thaw steps in Felts buffer (20 mM HEPES, 50 mM KCl, 5 mM
MgCl2, 0.01% (w/v) NP-40, freshly prepared 20 mM Na2MoO4, pH 7.2–7.3)
containing 1% protease inhibitor cocktail. The lysed sample was centrifuged
(15 200 × g, 10 min at 4 °C), and the protein concentration of supernatant was
analysed by BCA assay. The supernatant was mixed with Protein G Sepharose 4
Fast Flow (GE Healthcare) and rotated at 4 °C for 1 h. After removal of the beads,
the remaining supernatant was mixed with anti-ﬂuorescein antibody (Abcam,
ab19491, 1:240) and rotated at 4 °C for 1 h, followed by addition of fresh Protein G
Sepharose 4 Fast Flow and further incubation at 4 °C for 1 h. The beads were
washed ﬁve times with RIPA buffer and once with PBS. Proteins were eluted from
the beads by addition of 2 × sample buffer containing 100 mM DTT and boiling at
95 °C for 5 min. The samples were resolved by 7.5% SDS-PAGE, and the ﬂuor-
escent band corresponding to ﬂuorescein-modiﬁed Hsp90 was excised from in-gel
ﬂuorescence image. The excised gel was subjected to in-gel digestion using MS
grade Trypsin (Thermo Fisher Scientiﬁc). The peptide fragments were analysed by
nanoﬂow reverse liquid chromatography followed by tandem MS, using a LTQ
Orbitrap XL hybrid mass spectrometer as described above. Searches were per-
formed using the SEQUEST HT against the latest uniprot database for Hsp90 alpha
(HS90A_HUMAN, P07900) and Hsp90 beta (HS90B_HUMAN, P08238).
In vitro labelling of N-terminal domain of Hsp90α. Recombinant Hsp90α N-
terminal domain was obtained as described in Supplementary Methods. The solution
of Hsp90α N-terminal domain (6.4 µM) was incubated with 12 (10 µM) in PBS at 37 °
C. Aliquots at different time points were taken and then desalted using a Ziptip-C4.
The modiﬁcation yields were determined by MALDI-TOF MS (matrix: sinapic acid)
Peptide mapping of N-terminal domain of Hsp90α. The 12-modiﬁed N-
terminal domain of Hsp90α was puriﬁed by size-exclusion chromatography as
described above. The puriﬁed protein was denatured by urea (at a ﬁnal con-
centration of 2 M), followed by tryptic digestion (Trypsin/substrate ratio= 1/10
(w/w)) at 37 °C for 18 h. The digested peptides were separated by RP-HPLC and
characterised by MALDI-TOF MS and MS/MS (matrix: CHCA).
Cell viability assay. SKBR3 cells (6 × 104 cells) were seeded on a 12 well plate
(Corning) and incubated in McCoy’s 5A supplemented with 10% FBS for 48 h at
37 °C under 5% CO2. After washing twice with HEPES-modiﬁed McCoy’s 5A
(FBS-free) medium, the cells were incubated in the medium containing PU-H71 or
12 (0.3–10 µM) for 3 h at 37 °C. The cells were washed twice with McCoy’s 5A
supplemented with 10% FBS and further incubated for 69 h. As a control experi-
ment, the cells were treated with PU-H71 for 72 h. The cell viability was assessed
using Cell Counting Kit-8 (Dojin). The absorbance of each well was measured at
450 nm with inﬁnite M200 (TECAN).
Western blotting of Hsp90 client proteins. SKBR3 cells (2 × 105 cells) were
seeded on a 12 well plate and incubated in McCoy’s 5A supplemented with 10%
FBS for 48 h at 37 °C under 5% CO2. After washing twice with HEPES-modiﬁed
McCoy’s 5A (FBS-free) medium, the cells were incubated in the medium con-
taining PU-H71 (10 µM) or 12 (1–10 µM) for 3 h at 37 °C. The cells were washed
twice with McCoy’s 5A supplemented with 10% FBS and further incubated for 21
h. The cells were washed with PBS, and lysed with RIPA buffer containing 1%
protease inhibitor cocktail. The lysed samples were centrifuged (15 200 × g, 10 min
at 4 °C). The protein concentrations of supernatant were analysed by BCA assay,
and the normalised lysates were mixed with 1/4 volume of 5 × sample buffer
containing 250 mM DTT and vortexed for 1 h at room temperature. The samples
were subjected to Western blotting analysis using anti-HER2 (CST, #2242, 1:1000),
cRaf (CST, #53745, 1:1000), pAkt (CST, #4060, 1:2000), Akt (CST, #4691, 1:1000),
and beta actin (Abcam, ab8226, 1:1000) antibodies.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding authors on reasonable request.
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